NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Friday that it completed its acquisition of autoimmune diagnostics firm Crescendo Bioscience.
Myriad paid $245 million in cash for the deal. The total consideration was $270 million minus $25 million for the repayment of a loan made to Crescendo by Myriad in 2011, Myriad said in a document filed with the US Securities and Exchange Commission.
Crescendo, which is keeping its name, will operate as a wholly owned subsidiary of Myriad.